SCHEMBL5010908

SCHEMBL5010908

O=C(NCc1cc(F)cc(F)c1)c1cc(NC(=O)c2cc(F)c(F)cc2Cl)[nH]n1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PPARG P37231 10/20 0.44
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
PYGL P06737 1/20 0.39
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
POLB P06746 1/20 0.38
APEX1 P27695 1/20 0.38
NR1I2 O75469 1/20 0.38
ALDH1A1 P00352 1/20 0.37
ALOX15 P16050 1/20 0.37
HTT P42858 1/20 0.37
RECQL P46063 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5013662 0.90 PPARG (0.48) PPARGHSP90AA1HSP90AB1POLBNR1I2
SCHEMBL5013675 0.89 PPARG (0.48) PPARGALDH1A1MEN1KMT2A
SCHEMBL5008489 0.88 PPARG (0.51) PPARGNPC1RAB9AMEN1KMT2A
SCHEMBL5012182 0.88 PPARG (0.56) PPARGNPC1RAB9A
SCHEMBL5010405 0.88 PPARG (0.59) PPARGNPC1RAB9AHSP90AA1HSP90AB1
SCHEMBL14587723 0.87 PPARG (0.47) PPARGHTTMEN1KMT2A
SCHEMBL5012069 0.86 WDR5 (0.44) PPARGNPC1RAB9ANR1I2HTT
SCHEMBL5010706 0.86 PPARG (0.47) PPARGNPC1RAB9ANR1I2HTT
SCHEMBL5010627 0.86 PPARG (0.47) PPARGNPC1RAB9APYGLNR1I2
SCHEMBL5013431 0.86 NPC1 (0.49) PPARGNPC1RAB9APOLBNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL PPARG 706/4885NPC1 2838/4885RAB9A 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.